Cargando…

CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis

Cutaneous leishmaniasis (CL) affects the lives of 0.7–1 million people every year causing lesions that take months to heal. These lesions can result in disfiguring scars with psychological, social and economic consequences. Antimonials are the first line of therapy for CL, however the treatment is l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thacker, Seth G, McWilliams, Ian L., Bonnet, Beatrice, Halie, Lydia, Beaucage, Serge, Rachuri, Swaksha, Dey, Ranadhir, Duncan, Robert, Modabber, Farrokh, Robinson, Stephen, Bilbe, Graeme, Arana, Byron, Verthelyi, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075640/ https://www.ncbi.nlm.nih.gov/pubmed/32109251 http://dx.doi.org/10.1371/journal.pntd.0008050

Ejemplares similares

Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates
por: Puig, Montserrat, et al.
Publicado: (2006)

The Pentavalent Antimony Compounds in Tropical Medicine
por: Schmidt, Hans
Publicado: (1928)

New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony
por: Shin, Ji Yeon, et al.
Publicado: (2013)

Pentavalent Antimonials: New Perspectives for Old Drugs
por: Frézard, Frédéric, et al.
Publicado: (2009)

Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review
por: Brito, Nayara Castelano, et al.
Publicado: (2017)

Assessment of Immune and Clinical Response in Patients with Mucosal Leishmaniasis Treated with Pentavalent Antimony and Pentoxifylline
por: Cincura, Carolina, et al.
Publicado: (2022)

Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
por: Ferreira, Weverson A., et al.
Publicado: (2014)

Renal function evaluation in patients with American Cutaneous Leishmaniasis after specific treatment with pentavalent antimonial
por: Oliveira, Rodrigo A, et al.
Publicado: (2012)

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review
por: Berbert, Taisa Rocha Navasconi, et al.
Publicado: (2018)

American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
por: Marques, Sílvio Alencar, et al.
Publicado: (2019)

A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis
por: Rodrigues, Bruna Côrtes, et al.
Publicado: (2020)

Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model
por: Golali, Ensieh, et al.
Publicado: (2012)

The effect of CpG-ODN on antigen presenting cells of the foal
por: Flaminio, M Julia BF, et al.
Publicado: (2007)

First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony
por: Miranda-Verastegui, Cesar, et al.
Publicado: (2009)

A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
por: Martins, Sofia Sales, et al.
Publicado: (2021)

Reactions Following the Administration of the Pentavalent Compounds of Antimony: An Analysis of Cases Reported by Several Correspondents
por: Napier, L. Everard
Publicado: (1926)

Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs
por: Grajkowski, Andrzej, et al.
Publicado: (2005)

Effect of CpG ODN on monocytic myeloid derived suppressor cells
por: Shirota, Hidekazu, et al.
Publicado: (2012)

TRAIL is involved in CpG ODN-mediated anti-apoptotic signals
por: LIM, EUN-JUNG, et al.
Publicado: (2011)

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
por: Carrió, Jaume, et al.
Publicado: (2002)

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a Leishmania infantum Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy
por: Diotallevi, Aurora, et al.
Publicado: (2021)

The Extraordinary Case of a Woman with a 30-Year-Long Diffuse Leishmaniasis Cured with One Single Ampoule of Intranasal Pentavalent Antimoniate
por: Gonçalves, Sheila V. C. B., et al.
Publicado: (2023)

Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial
por: Ursu, Renata, et al.
Publicado: (2015)

Methodology of Clinical Trials Aimed at Assessing Interventions for Cutaneous Leishmaniasis
por: Olliaro, Piero, et al.
Publicado: (2013)

Limited Effect of CpG ODN in Preventing Type 1 Diabetes in NOD Mice
por: Lee, Byong Jun, et al.
Publicado: (2005)

Toll-like receptor 9 interaction with CpG ODN – An in silico analysis approach
por: Zhou, Wei, et al.
Publicado: (2013)

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
por: Gungor, Bilgi, et al.
Publicado: (2014)

Identification of Differentially Expressed lncRNAs in a CpG ODN-Activated Macrophage
por: Zheng, Ying, et al.
Publicado: (2020)

Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
por: Ito, Sayami, et al.
Publicado: (2020)

“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia
por: Eid Rodríguez, Daniel, et al.
Publicado: (2019)

Evaluation of Leishmanization Using Iranian Lizard Leishmania Mixed With CpG-ODN as a Candidate Vaccine Against Experimental Murine Leishmaniasis
por: Keshavarzian, Nafiseh, et al.
Publicado: (2020)

The Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice
por: Hejazi, H, et al.
Publicado: (2010)

Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation
por: De Cecco, Loris, et al.
Publicado: (2013)

CpG-ODN Class C Mediated Immunostimulation in Rabbit Model of Trypanosoma evansi Infection
por: Kumar, Parveen, et al.
Publicado: (2015)

Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways
por: Wu, Jiahui, et al.
Publicado: (2016)

Radiosensitization by CpG ODN7909 in an epidermoid laryngeal carcinoma Hep-2 cell line
por: Wang, Shu, et al.
Publicado: (2017)

Metalloproteinases and their Inhibitors under the Course of Immunostimulation by CPG-ODN and Specific Antigen Inhalation in Equine Asthma
por: Barton, Ann Kristin, et al.
Publicado: (2019)

Treatment with phosphodiester CpG-ODN ameliorates atopic dermatitis by enhancing TGF-β signaling
por: Ham, Won-Kook, et al.
Publicado: (2021)

TLR9-mediated ARF6 activation is involved in advancing CpG ODN cellular uptake
por: Wu, Jing-Yiing, et al.
Publicado: (2012)

High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors
por: Sommariva, Michele, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1s6oql0923gfo5b952m9cv7kg4